BioSpace News Archive

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today JCO Precision Oncology has published a study1 that highlights the development and validation of a breast cancer polygenic risk score (PRS) for women of all ancestries.

RAM Medical Corporation L.L.C., based in UAE and Germany, has recently set up its headquarters in Dubai.

Sight Sciences, Inc. today announced International Ophthalmology has published clinical data demonstrating the safety and effectiveness of the OMNI Surgical System.

KeifeRx, LLC announced today that its Chief Executive Officer Chris Hoyt will present at BioFuture 2022 being held November 7-9, 2022.

Apellis Pharmaceuticals, Inc. announced that results from the long-term extension study of EMPAVELI® in adults with paroxysmal nocturnal hemoglobinuria will be presented at the American Society of Hematology Annual Meeting being held Dec. 10-13 in New Orleans, Louisiana.

Sutro Biopharma, Inc. announced that data from the Company’s compassionate use program on anti-leukemic activity of STRO-002, a novel folate receptor-α targeting ADC, in infants and children with relapsed/refractory CBF2AT3-GLIS2 acute myeloid leukemia will be reviewed in an oral presentation at the 64th American Society of Hematology Annual Meeting and Exposition.

Orchard Therapeutics announced early clinical findings from its ongoing proof-of-concept study of investigational OTL-201 in MPS-IIIA will be featured in an oral presentation at the 64th American Society of Hematology Annual Meeting & Exposition, taking place December 10-13, 2022, in New Orleans.

Kura Oncology, Inc. announced that four abstracts highlighting ziftomenib, the Company’s potent and selective menin inhibitor, have been accepted for presentation at the upcoming American Society of Hematology Annual Meeting, to be held in New Orleans from December 10-13, 2022.

Neoleukin Therapeutics, Inc., “Neoleukin”, announced an oral presentation at the upcoming American Society of Hematology Annual Meeting and Exposition taking place December 10-13, 2022 in New Orleans, Louisiana.

Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced two upcoming data presentations at the American Society of Hematology (ASH) 2022 Annual Meeting.